Lefamulin: The First Systemic Pleuromutilin Antibiotic

Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

(2020) Thomas Lodise et al.   Open Forum Infectious Diseases

Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial

(2019) Thomas M File et al.   CLINICAL INFECTIOUS DISEASES

Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015–2016 and Characterization of Resistance Mechanisms

(2019) Rodrigo E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016)

(2019) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

(2019) Sujata M Bhavnani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia

(2019) Elizabeth Alexander et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

(2018) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid

(2016) M. Zeitlinger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pleuromutilins: Potent Drugs for Resistant Bugs—Mode of Action and Resistance

(2016) Susanne Paukner et al.   Cold Spring Harbor Perspectives in Medicine

A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism

(2016) Zohar Eyal et al.   Scientific Reports

Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections

(2014) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase II Clinical Study of BC-3781, a Pleuromutilin Antibiotic, in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections

(2013) W. T. Prince et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010

(2013) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections

(2012) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

(2012) H. S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pleuromutilin and its Derivatives-The Lead Compounds for Novel Antibiotics

(2011) Y. -Z. Tang et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY